A post-marketing registry-based prospective cohort study of long-term safety of risankizumab in Denmark and Sweden

First published 22/02/2021

Last updated 26/03/2025

EU PAS number:

EUPAS39351

Study

Ongoing

Documents

Study protocol

Initial protocol

p19633-protocol abstract-pmos-04sep2020_Redacted

English (180.77 KB - PDF) View document

Updated protocol

p19633-protocol-V1.6_Abstract_Redacted

First published: 22/02/2024

English (693.4 KB - PDF) View document

Study results

Study report

Other information

Study, other information

DoI_all combined.pdf

English (295.47 KB - PDF) View document

Secondary tabs